other neurodegenerative diseases involve a series of brain proteins, referred to as 'amyloidogenic proteins', with exceptional conformational plasticity and a high propensity for self-aggregation. Although the mechanisms by which amyloidogenic proteins kill neural cells are not fully understood, a common feature is the concentration of unstructured amyloidogenic monomers on bidimensional membrane lattices. Membranebound monomers undergo a series of lipid-dependent conformational changes, leading to the formation of oligomers of varying toxicity rich in β-sheet structures (annular pores, amyloid fibrils) or in α-helix structures (transmembrane channels). Condensed membrane nano-or microdomains formed by sphingolipids and cholesterol are privileged sites for the binding and oligomerisation of amyloidogenic proteins. By controlling the balance between unstructured monomers and α or β conformers (the chaperone effect), sphingolipids can either inhibit or stimulate the oligomerisation of amyloidogenic proteins. Cholesterol has a dual role: regulation of protein-sphingolipid interactions through a fine tuning of sphingolipid conformation (indirect effect), and facilitation of pore (or channel) formation through direct binding to amyloidogenic proteins. Deciphering this complex network of molecular interactions in the context of age-and disease-related evolution of brain lipid expression will help understanding of how amyloidogenic proteins induce neural toxicity and will stimulate the development of innovative therapies for neurodegenerative diseases.
The discovery that a significant proportion of cellular proteins do not have a well-defined structure under physiological conditions is one of the most fascinating concepts in modern biology (Ref. 1). This iconoclastic finding has shaken the broadly accepted dogma that a protein is predisposed to fold into a unique structure that is specified by its amino acid sequence.
Proteins that lack a well-defined 3D structure have been referred to as 'intrinsically disordered proteins' (IDPs), and they constitute the part of the proteome called the 'unfoldome' (Ref. (Fig. 1) , from a natively unfolded (mostly disordered) state to different α-helical or β-structural species folded to a different degree (Ref. 5 ). The protein can also self-aggregate and form various types of supramolecular assemblies with different morphology, including oligomers, amorphous aggregates and amyloid-like fibrils (Ref. 5) . This incredible level of conformational plasticity is also a hallmark of other amyloidogenic proteins, such as amyloid β (Aβ; encoded by APP) involved in Alzheimer disease and the prion protein (PrP; encoded by PRNP) involved in Creutzfeldt-Jakob disease and prion infections (Ref.
6). Some amyloidogenic proteins (Alzheimer Aβ peptides, α-synuclein) belong to the IDP family; in other cases (e.g. PrP), the protein has a 3D structure but can misfold into an alternative structure that is prone to aggregation. There are several mechanisms by which an amyloidogenic protein can acquire a disease-related 3D structure: overexpression, mutations or other genetic alterations, and exposure to harmful environmental conditions (Ref. 2). These mechanisms have been extensively studied during the past two decades. However, how amyloidogenic proteins induce cell death in these neurodegenerative diseases is still a mystery. Given the high prevalence and the fatal outcome of these pathologies in humans, this is clearly one of the most important challenges of biomedical research for the 21st century.
Among the different research strategies in this field, those aiming at identifying common features in distinct amyloidogenic proteins have been particularly fruitful. Obviously, it is somewhat paradoxical that the similar behaviour of amyloidogenic proteins -that is, their conformational plasticity and aggregation properties -does not rely on any kind of homology in their amino acid sequence. Instead, these common features might involve the 3D structures of these proteins. A major breakthrough was the identification of a common epitope in oligomers formed by various amyloidogenic proteins (Ref. 7) . This discovery suggested a universal mode of oligomerisation underlying a common mechanism of toxicity. Moreover, conformationdependent antibodies that recognise generic epitopes have been used as a structural basis to distinguish amyloid prefibrillar and fibrillar oligomers (Ref. 8) . A second breakthrough was the demonstration that amyloidogenic proteins can assemble into annular structures forming amyloid pores with ion channel properties (Refs 9, 10) (Fig. 1 ). This finding suggested that amyloid oligomers could perturb membrane permeability (e.g. cellular calcium fluxes) and thus kill neuronal cells more efficiently than amyloid fibrils. This mechanism, originally proposed by Arispe et al. (Refs 11, 12) for explaining the toxicity of Aβ, is now commonly referred to as the β-amyloid calcium channel hypothesis (Ref. 13) . However, despite their fruitful contribution to the field, these important discoveries did not really inform us on the molecular mechanisms involved in the different modes of amyloid oligomerisation and aggregation.
To progress towards this knowledge, we have to consider another common feature tightly linked to the biology of amyloids in the brain, which lies in their immediate environment -that is, biological membranes ( Refs 13, 14) . Indeed, Aβ peptides are generated by the proteolytic cleavage of a transmembrane precursor (the amyloid protein precursor, APP) (Ref. 15 Oligomers with a β-sheet structure can form protofibrils (d), amyloid fibrils (e) and amyloid pores (annular protofibrils) with ion-channel properties (f). In some instances (e.g. for α-synuclein), transmembrane channels can also be generated by oligomers with an α-helix structure (g). In all cases, the formation of functional ion channels requires the insertion and assembly of the oligomers in the neuronal membrane (green lipid bilayer). Note the possibility of conversion between α-and β-oligomers (h).
trafficking and signalling functions (Ref. 22) and are also preferential sites for host interactions with pathogens and toxins (Ref. 23) .
The aim of this review is to emphasise the specific role of cholesterol and sphingolipids, alone and in combination, in the interaction between amyloidogenic proteins and neural membranes, and to figure out how these interactions can affect the structural and functional properties of these proteins. We also discuss the impact of ageand disease-related changes in brain lipid content on the pathophysiology of amyloid-associated neurodegenerative diseases. We do not intend to present a separate section for each amyloidogenic protein (Aβ, α-synuclein, PrP, etc.). Instead, it is our goal to identify common membrane-based mechanisms that, at least at the molecular level, might apply to any type of amyloidogenic protein and thus could serve as a solid biochemical background for studying amyloid toxicity in the brain.
Mechanisms of concentration of amyloidogenic proteins on neuronal membranes Reduction of dimensionality
There are two main mechanisms ensuring the efficient transfer of amyloidogenic proteins from the cytosolic or extracellular milieu to neuronal plasma membranes. The first one is the reduction of dimensionality (from 3D to 2D) that occurs when a soluble protein dissolved in the bulk solvent binds to a membrane surface (Ref. 24) . The underlying idea is that the membrane 2D space can concentrate proteins far more efficiently than the 3D space of the bulk solvent. As a consequence, the average distance between two proteins is shorter in 2D than in 3D, and this effect is more pronounced for higher protein concentrations (Ref. 25) . This means that increased concentration of a protein lowers the average protein-protein distance more efficiently on a 2D surface than in a 3D space. Consequently, protein-protein interactions are favoured in the 2D space. This phenomenon is particularly important for amyloidogenic proteins that tend to selfaggregate after a conformational transition (Fig. 2) . Thus, the simple fact of the concentration of monomers in a restricted membrane area is, by itself, a crucial step in the complex process of amyloid oligomerisation/ aggregation.
Specific binding to membrane lipids
The second mechanism explaining the affinity of amyloidogenic proteins for neuronal membranes is lipid specificity. Converging data obtained from various laboratories with a broad range of experimental approaches have shown that amyloidogenic proteins interact with the lipids found in the Lo phase -that is, sphingolipids and cholesterol (Fig. 2) 19 ). This type of interaction has been extensively studied for α-synuclein, which recognises anionic phosphatidylserine and phosphatidylglycerol (Refs 36, 37, 38, 39). In this review, we restrict our analysis to the role of cholesterol and sphingolipids in the interaction of amyloidogenic proteins and membranes. As we will see, these lipids play a more active role in the conformation, oligomerisation and aggregation of amyloidogenic proteins than just acting as a concentration platform. Cracking the code governing glycosphingolipid-protein interactions Despite this huge structural diversity, glycosphingolipids can share common structural fingerprints that render them 'readable' by the same protein. This is the case for the glycosphingolipids GalCer, globotriaosylceramide (Gb 3 ) and GM3, which have a distinct sugar moiety but a common galactosyl residue with the same orientation (Fig. 3a-c) . As a logical consequence of this common structural feature, a protein that recognises one of these glycosphingolipids (e.g. GalCer), through binding to this galactose residue, might also interact with the other two (in this case, Gb 3 and GM3). This means that the biochemical code governing glycosphingolipid-protein interactions is degenerate. An example of this striking property is the V3 loop domain of the human immunodeficiency virus 1 (HIV-1) surface-envelope glycoprotein gp120, which was shown to recognise first GalCer (Refs 41, 42, 43), and then, several years later, both Gb 3 and GM3 (Refs 44, 45). However, there is a unique phase. In this case, monomers are not only concentrated on the membrane surface, but also undergo a major conformational change induced by the sphingolipids. This property is referred to as the chaperone effect of sphingolipids on amyloidogenic proteins. molecular mechanism that accounts for the interaction of each of these glycosphingolipids with gp120 (Ref. 46), and this mechanism also applies for amyloidogenic proteins. Let us first consider the way in which proteins bind to GalCer, which is both the major lipid of myelin sheaths (Ref. 47) and the simplest possible brain-expressed glycosphingolipid, consisting of a ceramide linked to a single galactosyl group (i.e. a ceramide monohexoside). Most of the GalCer molecule is dipped into the membrane, so that the galactosyl moiety is the principal region of the glycolipid available for protein binding. In this respect, there is a functional similarity between proteins that recognise GalCer and galactose-specific lectins. However, the local concentration of galactosyl groups in a nanodomain of GalCer is extremely high compared with the maximal concentration of free galactose in biological fluids (another illustration of the reduction-in-dimensionality concept discussed above). This explains why even high concentrations of free galactose cannot inhibit GalCer-gp120 interactions (Ref. 41). Moreover, the conformation of the galactose head group in the glycolipid is restricted by the ceramide backbone, which allows only limited motion of the sugar In these cases, the apolar side of the galactosyl ring fits particularly well with the aromatic-ring side chain of an aromatic residue (Phe, in this case) exposed at the surface of an amyloid protein (d). The electronic cloud of the π system stacks onto the CH groups of the galactosyl ring. This interaction is favoured by the common geometric structure of both rings, which allows a coordinated binding process between CH groups and π electrons. Cholesterol, which has a strong affinity for sphingolipids, can further improve the accessibility of the galactosyl group through fine tuning of glycosphingolipid conformation (e). This effect involves the establishment of an H-bond network between the OH group of cholesterol, the NH group of the sphingolipid and the oxygen atom of the glycosidic bond linking the ceramide and the sugar part of the sphingolipid. GalCer-NFA, GalCer with a nonhydroxylated fatty acid in the ceramide moiety. (Ref. 53 ). In both Gb 3 and GM3, the apolar side of the central galactosyl group has a similar orientation to that in GalCer (Fig. 3a-c) ; thus, GalCer-binding proteins are predicted to also bind to Gb 3 and GM3 through CH-π stacking. Note that the conformation of the sugar moiety of glycosphingolipids is restricted by a network of H-bonds (Ref. 52) that involves either an OH group in the acyl chain of the ceramide (intramolecular network) or the OH group of cholesterol (intermolecular network, Fig. 3e ), as further discussed below (see the section 'The outside and inside effects of cholesterol').
The notion that unrelated proteins, displaying a solvent-accessible aromatic residue in a hairpin domain, might bind these glycosphingolipids through a similar stacking mechanism has motivated the search for V3-like domains in various proteins, including amyloidogenic proteins (Ref. 27) . This is the concept of the glycosphingolipid-binding domain or, more generally, of the sphingolipid-binding domain (Ref. 49). Such domains are characterised by the presence, in a flexible region of the surface of a protein, of an aromatic residue with its side chain oriented towards the solvent, as illustrated in Figure 4a with the superimposition of the glycosphingolipid-binding domains of Aβ and α-synuclein (Ref. 31). The recognition of the glycosphingolipid by this region of the protein is thought to proceed through an induced-fit mechanism involving the conformational mobility of the aromatic side chain and a concomitant adjustment of the orientation of the galactosyl head group (Fig. 4b) .
In summary, a glycosphingolipid-binding domain is a flexible domain containing turninducing (Gly, Pro), basic (Arg, Lys, His) and aromatic residues (Phe, Tyr, Trp) (Refs 27, 54, 55, 56, 57). The critical involvement of aromatic residues in the interaction between proteins and glycosphingolipids has been convincingly demonstrated by using synthetic peptides in which these residues were replaced by Ala or Leu (Refs 53, 54, 55): correspondingly, the interaction with the glycosphingolipid has been dramatically decreased or even totally lost. Reciprocally, conservative aromatic substitutions (e.g. Phe to Trp) did not affect binding to glycosphingolipids (Ref. 54) . Taken together, these data show that the sphingolipidbinding domain mediates specific proteinglycosphingolipid interactions driven by CH-π stacking of a sugar and aromatic residue (Refs 52, 58).
Glycosphingolipids exert a chaperone effect on amyloidogenic proteins Conformational changes mediated by sphingolipid-binding domains
One important consequence of proteinsphingolipid interactions is that the conformation of the protein can be significantly affected on binding to sphingolipids (Fig. 4b) as an endogenous seed for the formation of neurotoxic amyloid fibrils in Alzheimer disease (Refs 29, 61, 62, 63) . These data have not only strengthened the role of lipid rafts as preferential 66) . The structure of amyloidogenic proteins bound to GM1 depends on several physicochemical parameters, including pH, membrane fluidity, GM1-carrier lipid ratios, protein concentration and the absence or presence of cholesterol, which could explain the discrepancies reported in the literature. In any case, the available data suggest that lipid rafts could (1) modulate the conformational changes of unstructured monomers from the unfolded state to moreordered α or β structures, and (2) control the balance between α and β structures, which in turn determine the oligomerisation/aggregation status of amyloidogenic proteins. Kakio et al. (Ref. 59) have shown that the oligomerisation and aggregation of Aβ peptides occur in ganglioside-enriched domains of the plasma membrane. A possible sequence of events could be as follows: (1) soluble Aβ monomers bind to the sugar head group of gangliosides in cholesterol-sphingolipidenriched domains such as lipid rafts; (2) on binding to gangliosides, Aβ is constrained to adopt an α-helical structure; (3) as the protein density on the membrane increases, Aβ undergoes a conformational transition from an α-helix-rich structure to a β-strand-rich one; and (4) the ganglioside-bound Aβ complex with acquired secondary structures serves as a seed for amyloid fibril formation. Indeed, Aβ fibrils with high toxicity have been successfully generated in an acellular system using GM1-containing raft-like liposomes (Ref. 67) . Altogether, these data strongly support the concept that the ganglioside cluster can act as a chaperone able to lower the activation energy for the conformational changes of Aβ (Ref. 59 ). This scenario is also consistent with the involvement of the glycosphingolipid-binding domain in membrane-amyloid interactions (Refs 53, 64).
How glycosphingolipids could stabilise an α-helix and prevent amyloid formation Unstructured amyloidogenic proteins can adopt a wide range of conformations in water and in biological membranes (Fig. 1) . The conformational flexibility of the amyloid core peptide of amylin (NFGAILSS) has been studied by nuclear magnetic resonance (NMR) (Ref. 68 ). In a membrane-like micellar environment, this peptide can adopt three distinct classes of conformations owing to the wide flexibility of the peptide chain (Fig. 4b) . Correspondingly, the unique Phe residue of the motif has three main possible orientations (Ref. 53). On binding to a glycosphingolipid bearing an appropriately oriented galactosyl group (lactosylceramide in Fig. 4b ), the Phe residue stacks onto the sugar so that only one of the numerous peptide conformations is selected and locked.
This illustrates the potency of CH-π stacking interactions to stabilise a thermodynamically unstable conformation at a minimal energetic cost, just like a wedge can efficiently block a car on a sloping street (Ref. 49). This simple but efficient mechanism could allow raft glycosphingolipids to act as molecular chaperones inducing α-helix-rich structures in amyloidogenic proteins (Fig. 5) . In the case of PrP, the stabilisation of an α-helix structure is beneficial, because this can prevent protein misfolding and aggregation (Ref. 49). However, the α-helix conformation could also facilitate membrane insertion and channel/pore formation, leading to dramatic perturbations of membrane permeability, as shown for α-synuclein (Ref. 69 ). In addition, the chaperone effect of glycosphingolipids is not irreversible. Changing the physicochemical properties of the raft-protein complex, for example through oxidative damage to the proteins or lipids (Refs 70, 71), could theoretically induce the dissociation of the amyloid peptides from glycosphingolipids such as GalCer. Then, the sudden exposure of aromatic side chains would allow a tight packing (through π-π interactions) between adjacent helices. This would lead to the formation of a dimer, a key step in the generation of amyloid fibrils (Refs 72, 73), which is thought to proceed through an ordered polymerisation of β structures (Ref. 74) .
From this discussion, we would like to underscore (1) the key role of aromatic residues in the self-assembly of amyloid fibrils and (2) the chaperone effect of raft glycosphingolipids that could induce otherwise thermodynamically unstable α-helix structures of amyloid fibrilforming proteins. Indeed, most amyloidogenic proteins (including Aβ and PrP) have an amino acid sequence that is expected to form β but not α structures (Ref. 75) . These proteins are referred to as 'α-helix/β-strand discordant'. Lipid rafts can prevent those proteins from adopting the conformation they prefer, stabilising their structure in a 'forced' α conformation. This stabilisation can occur in the early biosynthetic pathway as demonstrated for PrP (Ref. 76 ). Inhibition of sphingolipid biosynthesis logically increases PrP misfolding into disease-associated β structures (Ref. 77 ). This mechanism seems to also apply for several neurotransmitter receptors (e.g. the nicotinic acetylcholine receptor) whose transport and assembly in the plasma membrane require the assistance of sphingolipids (Ref. How glycosphingolipids could promote α-helix structures in amyloidogenic proteins Expert Reviews in Molecular Medicine © Cambridge University Press 2010 Figure 5 . How glycosphingolipids could promote α-helix structures in amyloidogenic proteins. When bound to glycosphingolipids (GSLs) through the sphingolipid-binding domain, the aromatic residues of two vicinal amyloidogenic proteins cannot interact with each other and the protein is forced to adopt an α-helix conformation. The molecular mechanism of this interaction is the CH-π stacking between the galactosyl ring of GalCer and the aromatic residue of the protein. The α-helix structure of amyloidogenic proteins is not only present in membrane-bound monomers (as illustrated in Fig. 2 , right panel), but also in oligomeric α-synuclein channels (Fig. 1g) . The β-amyloid aggregation process is triggered when the glycosphingolipidprotein complex is destabilised, resulting in the release of the protein from its glycosphingolipid chaperone (a). In this new glycosphingolipid-free environment, the aromatic residues of two vicinal amyloidogenic proteins can interact together (b), inducing a drastic conformational change from an initial α-helix to a β-strand structure. Amyloid aggregation then results from the π-π-driven assembly of aromatic side chains (for a review, see Ref. 79) , forming amyloid dimers that in turn associate to form amyloid fibrils (as illustrated in Fig. 1e ). 
Effects of cholesterol on sphingolipid conformation
First, cholesterol has a major impact on the conformation of sphingolipids. The apolar part of sphingolipids (i.e. the most important part of the ceramide) interacts with the smooth face of cholesterol, whereas the OH group of cholesterol is accessible to the polar part of the sphingolipid (Ref. 18 ). In the case of glycosphingolipids, this OH group is involved in an H-bond network that restricts the conformation of the sugar moiety in a parallel orientation with respect to the membrane. This effect is particularly important when the ceramide contains a nonhydroxylated fatty acid (NFA, Fig. 3e ). Because this conformation of the sphingolipid is particularly suited for a sphingolipid-binding domain, cholesterol usually accelerates protein binding to sphingolipid (Ref. 99 ) and this also applies for amyloidogenic proteins (Ref. 52) . By contrast, when the sphingolipid contains a hydroxylated fatty acid (HFA), the OH group of cholesterol is excluded from the H-bond network and it cannot exert its conformational effect on the sphingolipid. In this case, cholesterol does not improve but rather perturbs the organisation of sphingolipids and can even inhibit glycosphingolipid binding to amyloidogenic proteins (Ref. 52). Thus, according to the distribution of HFAs versus NFAs in sphingolipids, an increase of membrane cholesterol can lead to opposite effects on sphingolipid-mediated amyloidogenic protein binding and aggregation. In any case, these effects are due to a fine tuning of sphingolipid conformation induced by cholesterol, and do not involve any kind of physical interaction between amyloidogenic proteins and cholesterol.
Amyloidogenic proteins interact first with sphingolipids and then with cholesterol
By contrast, the second mechanism involves a direct interaction between the amyloidogenic protein and cholesterol. Therefore, this effect requires the insertion of a part of the amyloid protein in the membrane; otherwise the protein would not be in physical contact with cholesterol. Devanathan et al. (Ref. 100) have shown that Aβ peptide aggregation on the bilayer surface requires a sphingomyelin-rich environment but can occur in the absence of cholesterol. This is in line with our hypothesis that sphingolipids are fully responsible for the initial binding of amyloidogenic proteins to lipid rafts, and that cholesterol is not directly involved at this stage. However, at the second step the presence of cholesterol may greatly facilitate peptide insertion into the bilayer. The preferential interaction of amyloidogenic proteins with lipid raft domains ensures that cholesterol is indeed present underneath the sphingolipids that have attracted the unstructured monomer (Fig. 6) . Once inserted in the membrane, the amyloidogenic protein will immediately find cholesterol and interact with its free side -that is, the face that is not in contact with sphingolipids (for a detailed explanation of cholesterol topology, see Ref. 18 ).
How cholesterol could regulate the formation of oligomeric pores and channels
By stimulating the oligomerisation of membraneinserted amyloidogenic proteins, cholesterol could facilitate the formation of a pore-like assembly displaying ion channel properties (Fig. 1) . Quist et al. (Ref. 10) have hypothesised that amyloid pore/channels provide the most direct pathway for inducing neurodegenerative effects, through loss of ionic homeostasis increasing cell calcium to toxic levels. The structure of amyloid pores, which have been observed by atomic force microscopy (Refs 9, 10), remains to be experimentally elucidated at the atomic level. Computational models have suggested that most amyloid pores are probably formed by a complex assembly of β-rich protofibrils or oligomers (Ref. 
Changes in lipid content of the brain: what impact on neurodegenerative diseases?
The involvement of gangliosides in several neurodegenerative diseases is not totally surprising if one considers that these sphingolipids are critical for neuronal integrity and plasticity (Ref. 108 ) and synaptic function (Ref. 109) . Since the probability of acquiring these diseases gradually increases with age, it is important to evaluate how ganglioside 
Perspectives
How amyloidogenic proteins kill neurons is still a mystery. In particular, as recently discussed by Butterfield and Lashuel (Ref. 130) , 'there remains a knowledge gap regarding the molecular-level details by which amyloid-forming proteins act on the membrane and induce membrane permeabilization'. Deciphering the complex interplay between amyloidogenic proteins and membrane lipids, especially sphingolipids and cholesterol, will certainly help to achieve a clearer view on this enigma. Several milestones have already been reached, which have inspired an important part of today's research efforts worldwide. Despite their lack of amino acid sequence homology, amyloidogenic proteins share a number of intriguing properties: (1) an important conformational plasticity, allowing the same protein to remain unordered or to form highly ordered α and β structures (Refs 4, 5); (2) self-oligomerising capacities that revealed unexpected common antigenic properties (Ref. 7); (3) the ability to form pore-like structures with ion channel properties (Refs 9, 10); (4) self-aggregating activity leading to fibrillation and plaque deposition (Ref. 131); and (5) common structural motifs allowing specific interactions with sphingolipids (Ref. 49) and cholesterol (yet uncharacterised) in lipid expert reviews raft domains of the plasma membrane. It is intriguing that HIV-1, which interacts with glycosphingolipids through the V3 domain of its surface glycoprotein gp120, can induce major neurological disabilities, identified as HIV-1-associated dementia (Ref. 110) . In this respect, it is also worth noting that the protein CLN3, involved in Batten disease (the juvenile form of neuronal ceroid lipofuscinosis), also binds to GalCer through a V3-like sphingolipid-binding domain (Ref. 132) . This neural disease is caused by a mutation in this domain, namely E295K (Ref. 133) , which is analogous to mutations E22K in Aβ, E46K in α-synuclein and E200K in PrP, all associated with inherited forms of neurodegenerative disease and located in the sphingolipid-binding domains of these proteins. At least for two of these proteins (PrP and α-synuclein), the substitution of an anionic glutamic acid side chain by a cationic lysine resulted in altered binding to membrane sphingolipids (Refs 27, 31). This further emphasises the key role of the sphingolipidbinding domain in neuronal diseases.
Future studies will be necessary to better evaluate the neurotoxicity of the various forms of amyloidogenic proteins, including monomers, oligomers and aggregates, and to understand how these different species cooperate to accelerate (or slow down) the onset of neurodegenerative symptoms. This will help to decide on a rational basis which therapeutic strategy should be used at the different stages of the diseases. This will be possible with the finding of nontoxic drugs specifically affecting amyloid channels (Ref. 134) 
